Every letter we have printed

Price competition selects against anything that adds cost without being visible to the buyer at the point of decision. Everything discussed in this piece falls into that category, which is why none of it is offered.

Anything that shortens red cell survival lowers the result independently of glycaemia. Haemoglobin variants interfere with some assay methods and not others. These are not exotic situations, and a value that does not fit the clinical picture deserves a different measurement rather than a firmer conclusion.

Fasting glucose and glycated haemoglobin can move in opposite directions over a short period and both be correct, because they describe different windows. Your table makes that visible in a way I have not seen elsewhere and I have borrowed it for teaching.

Recent strenuous activity moves several markers into ranges that look alarming and resolve in days. Anybody arranging their own testing should record what they did the day before, and almost nobody does.

Half-life is quoted as a single number for compounds whose elimination is not first-order across the whole range, and the number then propagates into schedule arithmetic that assumes it is. The assumption is stated in the source and lost thereafter.

The published pharmacokinetic parameters are derived from the approved formulations, and nothing establishes that material of unknown formulation behaves the same way. Excipients and concentration both affect absorption for compounds of this kind.

The tolerability profile of a multi-receptor compound is not the sum of the single-target profiles either, and it is discussed as though it were. Both directions of that assumption are unsupported.

Naming conventions have made this worse. A compound described by its number of targets tells you nothing about the balance between them, and the number has become a marketing property rather than a pharmacological one.

A mechanistic argument can be tested only where an outcome study exists to test it against, and in this class several widely repeated mechanistic claims have never met one. Listing which have and which have not would be a useful reference entry.

I priced a sterility and endotoxin package for a small batch last year and the cost per surviving vial was substantial but not prohibitive. The obstacle was not money. It was that no supplier I approached had a route to commission it, and none of them had ever been asked.

The market has settled on purity because purity is the value a chromatograph produces cheaply. It is a supply-side accident that has become a demand-side expectation, and nobody chose it.

Container closure integrity is the quiet half of this subject. A perfectly filled vial with a poorly seated stopper is not a sterile product a month later, and nothing on any document describes the seal. A crimp that turns under finger pressure is a finding a buyer can make without any instrument at all.

Syringes marked to fifty units exist and hold half a millilitre, with the same numbering scale. Somebody who has learned the arithmetic on a hundred-unit barrel and then picks up a fifty will get the volume right and the assumption wrong. It is worth a warning line.

Rounding conventions differ between calculators and the differences are not trivial at small volumes. Two tools given identical inputs will return different answers, and neither will say which convention it used.

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.

Every custody scheme I have seen assumes a single sample moving forward in time. Real programmes split samples, store halves, retest months later and combine results, and the record-keeping vocabulary has no way to describe that.

Chain of custody is the whole game and it is the part the certificate never describes. A report on a sample the seller selected and posted is a true report about that sample. Whether that sample represents the lot is a question the laboratory is in no position to answer and does not claim to.

I collect these images. Of the thirty-one on my desk, eleven link to a report, six link to a page of reports where finding the right one is guesswork, and fourteen link to nothing at all. The proportion that survive a single click is the number worth publishing.

The spread you reported is, by the standards of interlaboratory comparison in sectors I have worked in, unremarkable. That is not a criticism of your reporting; it is a correction to the alarm some readers will take from it. Two laboratories differing by a point on a chromatographic purity are behaving normally.

Any transposition of two residues preserves the intact mass exactly. So does a substitution that swaps one residue for another of the same composition. The set of molecules consistent with a given mass is not small, and describing a mass match as identity confirmation makes a claim about that whole set.

In defence of the retention-time comparison your article is rude about: run against a properly characterised standard on a stated method, co-elution plus a matching mass is genuinely strong evidence. The weakness is not the logic, it is that the standard is usually a previous lot of the same product.

Maintenance at a reduced dose has a thin evidence base compared with the escalation and target-dose literature, which is the opposite of where most people spend their time. That imbalance deserves stating every time maintenance is discussed.

Cost is a maintenance variable and it is treated as though it were outside the clinical question. For most people the sustainable dose is the affordable one, and a plan that ignores that will be abandoned rather than followed.

A publication that covers a supply chain has something to say about maintenance that a clinical publication cannot: the arrangement depends on a company continuing to exist, continuing to make the same thing and continuing to ship it. None of those is guaranteed over a decade.

A small plea for the supplementary tables. The withdrawal literature puts its most useful numbers there — adherence, attendance, concomitant support — and the main text prints the curve everybody reproduces.

The industry-funded and investigator-initiated withdrawal studies in this area differ systematically in follow-up length. That is a fact about funding rather than about biology, and it should appear in any summary table.

Incidence figures from placebo-controlled trials should always be quoted with the placebo arm beside them, and in secondary coverage they almost never are. The difference between arms is the finding; the raw proportion is not.

Duration of follow-up drives incidence mechanically: a longer study finds more of everything. Comparing rates between studies of different lengths without annualising is a category error and it is done constantly.

In this market the dose is a calculation performed by the buyer from a concentration they inferred, which introduces a source of variation absent from any trial. Anything read across from the trial literature carries that additional uncertainty.

Reported rates depend heavily on whether the study asked or waited to be told. Solicited and unsolicited adverse event collection produce different numbers from the same population, and the method is buried in the supplement.

Customs inspection is a break in custody that nobody records and everybody experiences. A parcel opened, examined and resealed by an authority is entirely lawful and entirely undocumented from the laboratory’s point of view.

Sealed does not mean unopened. A crimp seal can be lifted and replaced by anybody with the right tool, and the visual check most buyers perform would not detect it. Tamper-evident and sealed are different properties sold under one word.

Turnaround is the specification buyers actually choose on, and it is the one that quietly sets the method. A service promising a result within days is promising a short generic gradient, because nothing else fits the queue. Price and turnaround are method disclosures in disguise.

Comparing across programmes is impossible at present because none of them describes its purchasing protocol in enough detail to reproduce. Publishing the protocol matters more than publishing another result.

Material sold for research use is not approved for human use in any jurisdiction, and a discussion of ceilings in that context is a discussion about what has been studied rather than about what anybody should do. Your department is consistent on this and it is why I trust the rest of the coverage.

A studied maximum is not a physiological ceiling, and the two are conflated constantly. The highest dose in a trial is the highest dose somebody chose to study, usually for tolerability and cost reasons, and it carries no claim about what lies above it.

Temperature during transit is a custody question and is treated as a logistics one. A sample that spent two days above ambient has been altered in transit, and no signature anywhere records that it happened.

The retained-sample idea from an earlier letter belongs in this section too. If half the vial stays sealed with the buyer and half goes to the laboratory, a disputed result has a physical answer rather than a rhetorical one.

I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.

A note on scale. One of these services runs volumes that would be respectable for a contract laboratory in a regulated sector; another is a small operation with a short queue. Both issue documents that look alike and carry the same weight in a listing. The report format equalises what the operations do not.